Low Testosterone.
More Than Low Libido.

Testosterone peaks in the mid-20s and declines gradually thereafter. By menopause, levels are approximately 50% of peak values. The decline is gradual but cumulative.

Removing both ovaries causes an immediate, dramatic loss of testosterone — the ovaries produce ~50% of total female testosterone. This is the most acute form of female testosterone deficiency and is often inadequately managed.

Combined OCPs dramatically raise SHBG, binding testosterone and reducing free (bioavailable) testosterone. Some women's SHBG remains elevated for months or years after stopping — a phenomenon called 'persistent SHBG elevation.'

While oestrogen gets the attention at menopause, testosterone also declines — accelerating the fall in libido, energy and cognitive function that characterises this transition.

Cortisol competes for shared precursor hormones (DHEA/pregnenolone) with testosterone. Chronic adrenal demand for cortisol reduces available substrate for testosterone synthesis.

SSRIs reduce libido directly through serotonin-dopamine interactions and can lower testosterone. This is a frequently missed contribution to sexual dysfunction in women on antidepressants.

Testosterone is primarily synthesised during deep sleep. Chronic sleep deprivation directly reduces testosterone production.

Measures all testosterone — bound and unbound. Can appear 'normal' even when free testosterone is very low. Never rely on this alone.

The biologically active fraction. Most clinically relevant marker — reflects what's actually available to tissues. In women on the OCP or HRT, this is the key number to evaluate.

High SHBG binds more testosterone, leaving less free. The OCP raises SHBG dramatically. Low SHBG (seen in PCOS, insulin resistance) means more free testosterone — which can drive androgen symptoms even with low total levels.

Adrenal androgen precursor — a proxy for adrenal testosterone contribution. Low DHEA-S in a young woman suggests adrenal insufficiency; very high suggests PCOS or adrenal pathology.

The Global Consensus Statement on Menopausal Testosterone Therapy (2019) supports testosterone use for HSDD (hypoactive sexual desire disorder) in postmenopausal women. Studies also show benefits for energy, cognitive function and mood.

Typically prescribed as a compounded skin cream (Androfeme 1% where available, or compounded testosterone 1% in a suitable base) applied to the inner thigh or abdomen. Testogel (a male product) can be used off-label at female doses (~1/10th the male dose).

Target the upper end of the normal female physiological range — not supraphysiological levels. Regular monitoring (free testosterone, SHBG, haematocrit) every 3–6 months when initiating.

When used at appropriate female doses, testosterone is well-tolerated. Side effects at physiological doses are uncommon. Excess dosing causes acne, facial hair growth, voice changes and clitoral enlargement — all reasons to monitor carefully.

Full response takes 3–6 months. Libido improvements may come sooner; energy and cognitive benefits often follow. Do not abandon therapy prematurely.

The most potent natural testosterone booster. Compound movements (squats, deadlifts, bench press) 3–4 times per week stimulate testosterone and growth hormone, preserve muscle mass and improve insulin sensitivity.

Testosterone is primarily produced during deep (slow-wave) sleep. 7–9 hours consistently, with regular sleep/wake times, is non-negotiable for hormonal recovery.

Reducing cortisol load frees up shared precursor hormones (DHEA, pregnenolone) for testosterone synthesis. HRV-based breathwork, meditation and reducing overtraining all help.

Zinc (red meat, oysters, pumpkin seeds) is essential for testosterone synthesis. Vitamin D deficiency is strongly associated with low testosterone. Adequate healthy fat (avocado, olive oil, eggs) provides cholesterol-based precursors.

Alcohol directly suppresses testosterone production and increases aromatisation to oestrogen. Reducing intake has a measurable positive effect on the oestrogen-to-testosterone ratio.